A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma
暂无分享,去创建一个
R. Sullivan | K. Flaherty | Dennie T. Frederick | J. Wargo | A. Reuben | A. Sharpe | Z. Cooper | D. Lawrence | M. Hazar-Rethinam | A. Piris | P. Prieto | R. Corcoran | Vikram R. Juneja | B. Nadres | M. Mooradian | Brandon Nadres
[1] B. Neyns,et al. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors , 2016, Journal of Translational Medicine.
[2] P. Hwu,et al. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma , 2015, Cancer Immunology Research.
[3] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[4] A. Giobbie-Hurder,et al. Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma , 2014, Molecular Cancer Therapeutics.
[5] M. Ernstoff,et al. BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma , 2014, Cancer Immunology Research.
[6] R. Lufkin,et al. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program , 2014, Journal of Immunotherapy for Cancer.
[7] David E Fisher,et al. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes , 2013, Oncoimmunology.
[8] R. Sullivan,et al. Resistance to BRAF-targeted therapy in melanoma. , 2013, European journal of cancer.
[9] R. Sullivan,et al. BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.
[10] R. Sullivan,et al. Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2 , 2012, Journal of immunotherapy.
[11] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[12] R. Sullivan,et al. Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma , 2012, Journal of immunotherapy.
[13] J. Wilmott,et al. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.
[14] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[15] G. Mann,et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] K. Flaherty,et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.
[17] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[18] S. Rosenberg,et al. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.
[19] S. Kim-Schulze,et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[21] D. Tuveson,et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.
[22] M. Atkins,et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. , 2000, The cancer journal from Scientific American.
[23] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Longo,et al. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[26] R. Zárate,et al. Quantitative Cell-Free Circulating BRAF Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors , 2014 .
[27] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[28] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[29] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.